Genetic Technologies Limited (GTG:ASX)


right-arrow Created with Sketch. -0.001 (-5.26%)
MCAP $81.15M
Last trade 15.33pm 16/04/2021 20mins delayed

Latest Announcements

12/04/2021GTGGenetic Technologies Limited
09/04/2021GTGGenetic Technologies Limited
01/04/2021GTGGenetic Technologies Limited
10/03/2021GTGGenetic Technologies Limited
10/03/2021GTGGenetic Technologies Limited
09/03/2021GTGGenetic Technologies Limited
03/03/2021 Price SensitivePSGTGGenetic Technologies Limited
02/03/2021 Price SensitivePSGTGGenetic Technologies Limited

Company Overview

Genetic Technologies Limited is a molecular diagnostics company. The Company is engaged in the provision of molecular risk assessment for cancer. The Company offers predictive testing and assessment tools for physicians to manage women's health. The Company's lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company's subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. Genetic Technologies Corporation Pty. Ltd. is engaged in genetic testing. The Company has launched the BREVAGen test across the United States through Phenogen Sciences Inc.

GTG in the news

Search Previous Announcements